Healthcare entity
regulation is the sole category represented across all 1 tracked stories. APOLLO is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. EPP appears in 1 tracked Healthcare story from February 23, 2026.
Last mentioned: Feb 23, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
regulation is the sole category represented across all 1 tracked stories. APOLLO is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. EPP appears in 1 tracked Healthcare story from February 23, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 10 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering EPP. Shared-story counts are live from our verified record — not editorial picks.
APOLLO Data Readout
Expected release of Phase 2 data which will support the traditional NDA filing.
FDA CRL Issued
Disc Medicine receives a Complete Response Letter for bitopertin's accelerated approval application.
Strategic Pivot
Company announces shift to traditional approval pathway for EPP indication.
Disc Medicine is shifting its regulatory strategy for bitopertin in erythropoietic protoporphyria (EPP) after receiving a Complete Response Letter from the FDA. The company will now pursue a traditional approval pathway, with critical Phase 2 APOLLO trial data expected in the fourth quarter of 2026.
Source: finance.yahoo.com · tickerreport.com
EPP is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
